The Effect of a Self-Compassion-Based Mindfulness Psychoeducation Program on Perceived Stress and Continuous Hope Among Healthcare Students (SCBMP-HS)

August 19, 2026 updated by: Abdullah Usta, Ondokuz Mayıs University

The Effect of a Self-Compassion-Based Mindfulness Psychoeducation Program on Perceived Stress Levels and Levels of Continuous Hope Among Healthcare Students: A Randomized Controlled Trial

The aim of this study is to evaluate the effect of a 6-week self-compassion-based mindfulness psychoeducation program on perceived stress and continuous hope among healthcare students.

This study was designed as a single-blind, randomized controlled trial and was conducted during the spring semester of the 2024-2025 academic year among students enrolled in the Health Care Services Department at Trabzon University Tonya Vocational School. A total of 60 students who met the eligibility criteria and voluntarily agreed to participate were included in the study and randomly assigned to the intervention or control group.

The intervention group received a 6-week self-compassion-based mindfulness psychoeducation program, while the control group did not receive the psychoeducational intervention during the study period. Data were collected using a Demographic Information Form, the Perceived Stress Scale, and the Continuous Hope Scale. Perceived stress and continuous hope were assessed at baseline and at Week 6, immediately after completion of the intervention. Study data were analyzed using SPSS version 22.0.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Tonya
      • Trabzon, Tonya, Turkey (Türkiye), 61000
        • Tonya Vocational School

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Currently enrolled in the Department of Health Care Services
  • Aged 18 years or older
  • Willing to participate in the study and provide informed consent
  • Able to read and understand Turkish
  • No current psychiatric diagnosis and not receiving active psychiatric treatment
  • No participation in a mindfulness-, self-compassion-, or stress management-based psychoeducational program within the previous six months

Exclusion Criteria:

  • Current psychiatric diagnosis or active psychiatric treatment
  • Previous participation in a self-compassion- or mindfulness-based psychoeducational program within the previous six months
  • Inability to read and understand Turkish
  • Refusal to provide informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Self-Compassion-Based Mindfulness Psychoeducation Group

Participants in the intervention group received a 6-week Self-Compassion-Based Mindfulness Psychoeducation Program delivered through in-person group sessions at Trabzon University Tonya Vocational School. The program consisted of six sessions delivered once weekly.

Participants were divided into three subgroups of 10 participants for the delivery of the program. Each session was conducted by the researcher according to the structured psychoeducation program and lasted approximately 45-90 minutes.

The program included psychoeducational content and exercises focused on self-compassion, mindfulness, stress awareness, emotion regulation, and self-compassion-based coping skills.
Behavioral: SELF-COMPASSION-BASED MINDFULNESS PSYCHOEDUCATION PROGRAM

The Self-Compassion-Based Mindfulness Psychoeducation Program was delivered through in-person group sessions at Trabzon University Tonya Vocational School. The program consisted of six sessions delivered once weekly.

Participants in the intervention group were divided into three subgroups of 10 participants. Each session was conducted by the researcher according to the structured psychoeducation program and lasted approximately 45-90 minutes.

The program included psychoeducational content and exercises focused on self-compassion, mindfulness, stress awareness, emotion regulation, and self-compassion-based coping skills.
No Intervention: No-Intervention Control Group
Participants in the control group did not receive the Self-Compassion-Based Mindfulness Psychoeducation Program during the 6-week study period. After completion of the post-intervention assessment, participants in the control group were offered a single-session breathing exercise training.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Trait Hope Scale Total and Subscale Scores
Time Frame: Baseline and Week 6 (immediately after completion of the intervention)
Hope is assessed using the Trait Hope Scale, a 12-item measure consisting of two subscales: Agency Thinking and Pathways Thinking. Four items are filler items and are not included in scoring. Higher total scores indicate higher levels of hope. The scale is administered at baseline and at Week 6, immediately after completion of the psychoeducation program, to assess change in hope over time.
Baseline and Week 6 (immediately after completion of the intervention)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in Perceived Stress Scale Total and Subscale Scores
Time Frame: Baseline and Week 6 (immediately after completion of the intervention)
Perceived stress is assessed using the 8-item Perceived Stress Scale. The scale includes two subscales: Perceived Stress and Perceived Coping. Items are rated on a 5-point Likert scale from 0 to 4, and the total score ranges from 0 to 32. Higher total scores indicate higher levels of perceived stress. The scale is administered at baseline and at Week 6, immediately after completion of the psychoeducation program, to assess change in perceived stress over time.
Baseline and Week 6 (immediately after completion of the intervention)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Ondokuz Mayıs University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 1, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 20, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 20, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 13, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 19, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 24, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 24, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 19, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2025-584

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

I don't want to share it before it's published.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings